CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate

Journal of the American Academy of Dermatology

Volumn 58, Issue 3, 2008, Pages 480-484

  Leitenberger, Justin J ^a   Berthelot, Cindy N ^a   Polder, Kristel D ^a   Pro, Barbara ^b   McLaughlin, Peter ^b   Jones, Dan ^b   Duvic, Madeleine ^a  

^a University of Texas Health Science Center at Houston   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD56 ANTIGEN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOLIC ACID; PRALATREXATE; PREDNISONE; VINCRISTINE;

AGED; ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; DENDRITIC CELL; FEMALE; HUMAN; PLASMACYTOID DENDRITIC CELL TUMOR; PLASMACYTOMA; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; RELAPSE; REMISSION; SKIN BIOPSY; SKIN MANIFESTATION; STOMATITIS; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AMINOPTERIN; ANTIGENS, CD4; ANTIGENS, CD56; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; SKIN NEOPLASMS; TREATMENT OUTCOME; VINCRISTINE; VITAMIN B 12;

EID: 38949153794     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.12.012     Document Type: Article

References (23)

1. Chan J.K.C., Jaffe E.S., and Ralfikiaer E. Blastic NK-cell lymphoma. In: Jaffe E.S., Harris N., Stein H., et al. (Eds). Pathology and genetics of tumors of hematopoietic and lymphoid tissues (2001), IARC Press, Lyon, France 214-215
2. DiGiuseppe J.A., Louie D.C., Williams J.E., Miller D.T., Griffin C.A., Mann R.B., et al. Blastic natural killer cell leukemia/lymphoma: a clinicopathologic study. Am J Surg Pathol 21 (1997) 1223-1230
3. Bayerl M.G., Rakozy C.K., Mohamed A.N., Vo T.D., Long M., Eilender D., et al. Blastic natural killer cell lymphoma/leukemia: a report of seven cases. Am J Clin Pathol 117 (2002) 41-50
4. + cutaneous neoplasms: a distinct hematological entity?. Am J Surg Pathol 23 (1999) 137-146
5. + hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 127 (2007) 687-700
6. Garnache-Ottou F., Feuillard J., and Sass P. Plasmacytoid dendritic cell leukemia/lymphoma: towards a well defined entity?. Br J Haematol 136 (2007) 539-548
7. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 5 (1999) 919-923
8. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283 (1999) 1183-1186
9. + precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 26 (2002) 852-862
10. + blastic tumors of skin. Blood 101 (2003) 5007-5009
11. +) malignancies. Blood 99 (2002) 1556-1563
12. +) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 29 (2005) 1274-1283
13. + hematodermic neoplasms): a review. Am J Clin Pathol 123 (2005) 662-675
14. +) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer 94 (2002) 2401-2408
15. + hematodermic/hematolymphoid malignancy. J Am Acad Dermatol 44 (2001) 231-238
16. + malignancy and how should it be treated?. Bone Marrow Transplant 32 (2003) 637-646
17. Krug L.M., Ng K.K., Kris M.G., Miller V.A., Tong W., Heelan R.T., et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 6 (2000) 3493-3498
18. O'Connor O.A., Hamlin P.A., Portlock C., Moskowitz C.H., Noy A., and Straus D.J. Pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity. [abstract]. Blood 106 (2005) 2678
19. DeGraw J.I., Colwell W.T., Piper J.R., and Sirotnak F.M. Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 36 (1993) 2228-2231
20. Sirotnak F.M., DeGraw J.I., Schmid F.A., Goutas L.J., and Moccio D.M. New folate analogues of the 10-deazaaminopterin series: basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 12 (1984) 18-25
21. O'Connor O.A. Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 18 (2006) 591-597
22. Krug L.M., Azzoli C.G., Kris M.G., Miller V.A., Khokhar N.Z., Tong W., et al. 10-Propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res 9 (2003) 2072-2078
23. Fury M.G., Krug L.M., Azzoli C.G., Sharma S., Kemeny N., Wu N., et al. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer Chemother Pharmacol 57 (2006) 671-677